How is visceral fat measured?
Visceral fat is measured by imaging methods such as MRI, dual-emission X-ray absorptiometry, and bioelectrical impedance analysis, as well as by surrogate markers like serum resistin. This page summarises the measurement
How is visceral fat measured?
Visceral fat is the adipose tissue stored around internal organs. In research settings it is measured directly by magnetic resonance imaging (MRI), which can quantify subcutaneous fat, visceral fat, and fat content in the liver and pancreas [3]. Other approaches include dual-emission X-ray absorptiometry (DXA) for body composition [3] and bioelectrical impedance analysis (BIA), which provides measures of body fat percentage and visceral fat [4]. Surrogate markers such as serum resistin have also been studied as predictors of visceral fat reduction after sleeve gastrectomy [6].
The work centres on adipose tissue dysfunction and its relationship to insulin resistance, type 2 diabetes, and cardiometabolic risk [8].
Research Studies
Mazdutide and pancreatic fat fraction in overweight or obesity
A randomised, double-blind, placebo-controlled trial is evaluating mazdutide in patients with overweight or obesity and fatty pancreas. The primary endpoint is change from baseline in pancreatic proton density fat fraction (PDFF) measured by MRI at week 48. The study plans to enrol 194 participants [1].
Mazdutide and visceral fat in type 2 diabetes with NAFLD
A multicentre, prospective, randomised controlled investigator-initiated trial is assessing mazdutide in Chinese patients with type 2 diabetes mellitus and moderate-to-severe non-alcoholic fatty liver disease who have achieved glycaemic control. The study notes that Chinese patients with T2DM are susceptible to visceral fat accumulation, which increases cardiometabolic risk [2].
Sclerostin, irisin, and leptin in Chinese men with obesity
A cross-sectional study measured body composition by DXA and determined subcutaneous fat, visceral fat, and fat content in the liver and pancreas by MRI in 26 men with normal weight and 78 men with obesity. Serum sclerostin, irisin, and leptin were measured by ELISA. The study explored associations with body composition and bone mineral density [3].
BIA-derived visceral fat versus BMI in IVF outcomes
A prospective observational cohort study is evaluating whether body composition measured by BIA, including body fat percentage and visceral fat, predicts in vitro fertilisation outcomes better than body mass index. Participants undergo BIA prior to treatment [4].
Urolithin A and muscle preservation during weight loss
A study is testing whether daily Urolithin A (500 mg) for 6 months helps adults with obesity lose weight while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism. All participants receive a structured lifestyle programme [5].
Resistin and visceral fat reduction after sleeve gastrectomy
A study is investigating whether serum resistin levels before surgery can predict how much visceral fat a patient will lose following sleeve gastrectomy for morbid obesity. Visceral fat is closely linked to inflammation and type 2 diabetes [6].
Barley green and visceral fat area
A randomised study in individuals with high body fat percentage is investigating changes in visceral fat area and associated indicators under barley green supplementation combined with a calorie-restricted diet. The study also explores mechanisms via gut microbiota analysis [7].
Ethnic differences in adipose tissue dysfunction
A pilot study is investigating the relationship between type 2 diabetes and adipose tissue dysfunction across different ethnic groups. Adipose tissue dysfunction is characterised by abnormal fat distribution, including increased visceral, hepatic, and pancreatic fat, and elevated inflammatory biomarkers [8].
If you are reading this for personal health reasons
The compounds and materials described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Efficacy of Mazdutide on Fatty Pancreas
- [2] Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
- [3] Serum Bone-, Muscle- and Fat- Derived Factors Sclerostin, Irisin and Leptin Show Different Correlations With Body Composition and Bone Mineral Density in Chinese Men With Obesity: A Cross-Sectional Study.
- [4] BMI Versus Body Fat Percentage - Which is the Better Predictor of Fertility Outcomes in IVF Cycles?
- [5] Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.
- [6] Relationship Between Serum Resistin Levels and Reduction in Visceral Fat in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity
- [7] Effects of Barley Green on Visceral Fat Area in the Human Body and Investigation Into the Associated Mechanism of Intestinal Microbiota
- [8] Ethnic Differences in Adipose Tissue Dysfunction in the Development of Insulin Resistance and Type 2 Diabetes